• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    ir@repay.com



    Media Relations for REPAY:

    Kristen Hoyman

    khoyman@repay.com

    Get the next $CNDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Integra LifeSciences Holdings Corporation
    $IART
    7/9/2026$19.00Market Perform
    BMO Capital Markets
    Integra LifeSciences Holdings Corporation
    $IART
    6/18/2026$25.00Hold → Buy
    Argus
    Integra LifeSciences Holdings Corporation
    $IART
    5/28/2026$16.00Sell → Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    5/6/2026$125.00Neutral
    Citigroup
    Repay Holdings Corporation
    $RPAY
    5/5/2026$3.75Overweight → Equal-Weight
    Stephens
    Integra LifeSciences Holdings Corporation
    $IART
    4/15/2026Buy → Hold
    Argus
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Agadi Harshavardhan V bought $182,909 worth of shares (117,099 units at $1.56) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/23/26 5:21:51 PM ET
    $CNDT
    Real Estate

    Chief Executive Officer Agadi Harshavardhan V bought $313,720 worth of shares (220,000 units at $1.43) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/20/26 11:36:25 AM ET
    $CNDT
    Real Estate

    Director Palau Hernandez Margarita bought $72,650 worth of shares (50,000 units at $1.45) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/20/26 11:33:12 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sadek Zachary F

    3 - Repay Holdings Corp (0001720592) (Issuer)

    7/20/26 5:01:15 PM ET
    $RPAY
    Real Estate

    Director Letier A. Scott was granted 20,353 shares, increasing direct ownership by 3% to 737,298 units (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    7/16/26 4:02:09 PM ET
    $CNDT
    Real Estate

    SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 937 shares, decreasing direct ownership by 3% to 34,516 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    7/6/26 4:43:40 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on Integra with a new price target

    BMO Capital Markets initiated coverage of Integra with a rating of Market Perform and set a new price target of $19.00

    7/9/26 9:28:53 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra upgraded by Argus with a new price target

    Argus upgraded Integra from Hold to Buy and set a new price target of $25.00

    6/18/26 8:09:42 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra upgraded by Citigroup with a new price target

    Citigroup upgraded Integra from Sell to Neutral and set a new price target of $16.00

    5/28/26 8:44:41 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    REPAY and SBT Bring Compliant Text Communications and Payments to the Accounts Receivable Management and Financial Services Industries

    Integrating advanced payment processing and text messaging capabilities to deliver convenient customer interactions and streamline revenue workflows Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY"), a leading provider of bill payment solutions, and SBT, a leader in compliance-first conversational commerce, today announced a strategic partnership enabling financial service providers to efficiently coordinate consumer communications and receive payments via text. SBT ensures compliance with carrier requirements and industry regulations including the TCPA, FDCPA, and CFPB guidelines for text messaging across regulated industries. This approach gives consumers greater flexibility in when,

    7/16/26 8:30:00 AM ET
    $RPAY
    Real Estate

    Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

    PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/16/26 8:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

    At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively LIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA® (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and is the first F

    7/16/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    Repay Holdings Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Repay Holdings Corp (0001720592) (Filer)

    7/14/26 4:05:30 PM ET
    $RPAY
    Real Estate

    Conduent Incorporated filed SEC Form 8-K: Leadership Update

    8-K - CONDUENT Inc (0001677703) (Filer)

    7/2/26 5:01:24 PM ET
    $CNDT
    Real Estate

    Conduent Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CONDUENT Inc (0001677703) (Filer)

    6/30/26 1:40:33 PM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints Zach Sadek to its Board of Directors

    Board Strengthened with Independent Director with Significant Industry Experience Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of bill payment solutions, today announced that Zachary F. Sadek has been appointed to its Board of Directors, effective immediately. Mr. Sadek is a Senior Partner at Parthenon Capital Partners, an affiliate of one of the Company’s largest stockholders, PCP Managers II L.P. ("Parthenon Capital"), a growth-oriented private equity firm that partners with management teams to develop and implement bold strategic visions to make companies leaders in their markets. He brings more than two decades of experience investing in an

    7/13/26 5:32:00 PM ET
    $RPAY
    Real Estate

    Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer

    PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide. Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed activ

    7/2/26 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Announces Key Executive Appointments

    PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (NASDAQ:IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy. Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Ki

    6/23/26 8:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

    PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/16/26 8:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fre

    7/1/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forager Raises Proposal to Acquire Repay to $5.25 Per Share

    BIRMINGHAM, Ala., June 29, 2026 (GLOBE NEWSWIRE) -- Forager Capital Management, the largest shareholder of Repay Holdings Corporation (NASDAQ:RPAY)(the "Company"), with beneficial ownership of approximately 13% of the issued and outstanding shares, delivered an updated proposal to the Company’s Board of Directors to acquire the Company for $5.25 per share in cash following recent discussions with the Company. A copy of Forager’s letter to the Board is attached below. June 26, 2026 Repay Holdings Corporation3060 Peachtree Road NW, Suite 1100Atlanta, Georgia 30305Attention: Board of Directors Dear Members of the Board, We appreciate the Chairman taking the time to meet in person and foun

    6/29/26 8:30:00 AM ET
    $RPAY
    Real Estate